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Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) are complex
human brain disorders that affect an increasing number of people worldwide. With
the identification first of the proteins that aggregate in AD and FTLD brains and
subsequently of pathogenic gene mutations that cause their formation in the familial
cases, the foundation was laid for the generation of animal models. These recapitulate
essential aspects of the human conditions; expression of mutant forms of the amyloid-β
protein-encoding APP gene in mice reproduces amyloid-β (Aβ) plaque formation in AD,
while that of mutant forms of the tau-encoding microtubule-associated protein tau
(MAPT) gene reproduces tau-containing neurofibrillary tangle formation, a lesion that
is also prevalent in FTLD-Tau. The mouse models have been complemented by those
in lower species such as C. elegans or Drosophila, highlighting the crucial role for
Aβ and tau in human neurodegenerative disease. In this review, we will introduce
selected AD/FTLD models and discuss how they were instrumental, by identifying
deregulated mRNAs, miRNAs and proteins, in dissecting pathogenic mechanisms in
neurodegenerative disease. We will discuss some recent examples, which includes
miRNA species that are specifically deregulated by Aβ, mitochondrial proteins that are
targets of both Aβ and tau, and the nuclear splicing factor SFPQ that accumulates in
the cytoplasm in a tau-dependent manner. These examples illustrate how a functional
genomics approach followed by a careful validation in experimental models and human
tissue leads to a deeper understanding of the pathogenesis of AD and FTLD and ultimately,
may help in finding a cure.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative dis-
ease. It is characterized by the functional impairment and loss of
neurons, that results in a progressive decline inmemory and other
cognitive functions, leading to dementia (Ballard et al., 2011).
Frontotemporal dementia (FTD) is a related disorder that com-
prises a group of behavioral, language, and movement disorders.
On the basis of the nature of the characteristic protein inclusions,
frontotemporal lobar degeneration (FTLD) can be subdivided
into the more frequent FTLD-tau and FTLD-TDP subtypes, as
well as FTLD-FUS and FTLD-UPS that are less common (Mioshi
et al., 2010; Goedert et al., 2012). FTLD-Tau includes Pick’s dis-
ease (PiD), FTD with Parkinsonism linked to chromosome 17
(FTDP-17), argyrophilic grain disease (AgD), corticobasal degen-
eration (CBD) and progressive supranuclear palsy (PSP). FTLD
is the second most common form of dementia presenting before
the age of 65 (Liscic et al., 2008).
It has only been in recent years that it became widely accepted
that with an ageing population, AD and related disorders will
inevitably reach epidemic proportions. Worldwide numbers are
in the order of an estimated 35.6 million. By 2050, this figure
will have increased to a projected 115 million. The countries
or regions with the largest numbers of affected individuals are
China and the developing Western Pacific, Western Europe, and
the Unites States (Ballard et al., 2011). The latest figures released
by the Alzheimer’s Association clearly illustrate the dimension
of the problem (Alzheimer’s Association. 2012 AD facts and fig-
ures. Alzheimer’s and Dementia: The Journal of the Alzheimer’s
Association. March 2012; 8:131–168.): 5.4 million Americans are
living with AD. Another way to put this figure into perspective is
that one in eight older Americans has AD. This disease is the sixth-
leading cause of death in the United States and the only cause
of death among the top 10 in the United States that cannot be
prevented, cured or even slowed. While deaths from AD are dra-
matically rising (by 66% between 2000 and 2008), deaths from
other major diseases such as stroke (−20%), breast cancer (−3%)
or prostate cancer (−8%) are dropping. In caring for persons with
AD and other dementias, more than 15 million Americans pro-
vide unpaid care valued at $210 billion. Payments for care are
estimated to be $200 billion in the United States in 2012 alone.
These numbers are staggering and can be easily extrapolated to
other countries.
The importance of AD is also reflected by the research out-
put in the field. A PubMed search with the term “Alzheimer”
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identifies approximately 6000 papers in 2011 alone; it is there-
fore impossible to provide a comprehensive overview of the field.
Nonetheless, as this review article is part of a series aimed at cov-
ering systems biology approaches (e.g., to understand the role of
kinases) in diseases such as AD, it is important to put the sys-
tems biology approaches in AD and also the role of kinases in the
pathogenesis of AD into perspective. Starting with the initial dis-
covery of Alois Alzheimer of the key histopathological features of
a disease that would eventually bear his name, we will provide a
short overview of the studies that have lead to the identification
of the proteins that make up the hallmark lesions in AD. It will be
inevitable to discuss another form of dementia, FTLD-Tau, as it
shares important clinical and histopathological features with AD
(Jucker and Walker, 2011). We will then discuss those genes, for
which pathogenicmutations have been identified in familial cases.
Incidentally, they encode the proteins that form the hallmark
lesions in AD and FTLD or at least have a role in their for-
mation, strengthening the view that understanding their role in
disease is crucial for developing a cure (Goate and Hardy, 2012).
Clinically, the familial cases are identical to the more frequent
sporadic cases, except that they have an earlier onset. Insight into
the disease process has initially been obtained by the analysis of
human tissue, but with the identification of pathogenic muta-
tions it has been possible to establish transgenic animal models
that express the mutant forms. Modeling has been mainly done
in mice, but eventually also in lower species such as the fruit-
fly Drosophila melanogaster or the round-worm Caenorhabditis
elegans (Gotz and Ittner, 2008). The animal models recapitulate
the human pathology and have been instrumental in dissecting
underlying pathogenic mechanisms. With this insight, the mod-
els were successfully employed in developing treatment strategies
that guided clinical trials in human AD patients, such as Aβ-
targeted vaccinations (Gotz et al., 2012). As we will discuss in
detail, many animal and cellular models were further used to
identify deregulated genes, miRNAs and proteins, followed by
a functional validation in human tissue (Hoerndli et al., 2005).
Likewise, expression data in humans have been validated in exper-
imental systems. In the final part of this review article we will
discuss where we believe the AD field is heading and especially
the role we expect functional genomics approaches will have in
these endeavors.
FROM ALOIS ALZHEIMER’S LANDMARK DISCOVERY
IN 1907 TO THE LAST THIRTY YEARS OF USING
BIOCHEMICAL ANDMOLECULAR TECHNIQUES
2006 marked the 100th anniversary of a lecture the German
psychiatrist and neuropathologist Alois Alzheimer had given in
Tübingen, a city in the Southern part of Germany, presenting
the clinical and neuropathological characteristics of the disease
that his colleague Emil Kraepelin would subsequently name after
him (Alzheimer et al., 1995). The year of this anniversary saw
many excellent reviews highlighting the initial discoveries and
what the scientific community has achieved in the past hundred
years (Goedert and Spillantini, 2006; Roberson andMucke, 2006).
It was in November 1901 that Alzheimer admitted Auguste D., a
51-year-old patient, to the Frankfurt hospital because of progres-
sive memory loss, focal symptoms, delusions, and hallucinations.
When Auguste D. died in April 1906, her brain was sent to
Munich for a histopathological analysis. Alzheimer used a sil-
ver staining method developed by Max Bielschowsky a few years
earlier that is still in use today. This method was crucial for
him to identify the two key defining neuropathological char-
acteristics of AD, the neuritic plaques and the neurofibrillary
tangles (Figure 1). While plaques had been reported before in
a patient with epilepsy, Alzheimer was the first to describe the
tangle pathology. A few years later, he also discovered another
type of (spherical) lesion now known as Pick body. The cor-
responding disease was named PiD, after Arnold Pick, who
first described it in 1892 (Goedert and Spillantini, 2006). PiD
belongs to the spectrum of FTLD. While the presence of abnor-
mal deposits helped greatly with disease classification (Blessed
et al., 1968), it was only during the past thirty years that their
molecular composition and role in the pathological process was
elucidated.
The plaques are extracellular deposits, whereas the tangles
form intraneuronally. The two lesions have the filamentous
nature of their respective protein components in common, and
both types of filaments can be visualised by electron microscopy.
After they were first described in the early 1960s, it took
another twenty years until their major constituents were iden-
tified, amyloid-β (Aβ) as the principal plaque component, and
tau as the principal tangle component (Figure 1). Aβ has a size
of mainly 40–42 amino acids and is derived by proteolytic cleav-
age from the larger amyloid precursor protein, APP (Glenner
and Wong, 1984; Masters et al., 1985). β-Secretase generates the
amino-terminus of Aβ and γ-secretase dictates its length, with
Aβ40 being the more common and Aβ42 the more fibrillogenic
and neurotoxic species. Aβ forms toxic oligomeric aggregates
and eventually deposits as plaques. Additional products of APP
processing are an amino-terminal fragment that is released by
shedding, and AICD, the Aβ intracellular cytoplasmic domain. β-
Secretase activity has been attributed to a single protein, BACE
(Vassar et al., 1999), whereas γ-secretase activity depends on four
components, presenilin, nicastrin, APH-1 and PEN-2 (Edbauer
et al., 2003). α-Secretase is involved in the non-amyloidogenic
pathway by cleaving APP within the Aβ domain, thus precluding
Aβ formation (Lammich et al., 1999). More recent studies iden-
tified additional species of Aβ, such as pyroglutamate-modified
forms of Aβ or species ranging from 39 to 43 amino acids, that
all to some degree or another are believed to have a role in dis-
ease initiation (Saito et al., 2011; Cynis et al., 2008). Historically,
it was the mapping of the APP gene to chromosome 21, together
with the observation of plaques and tangles in most elderly indi-
viduals with Down’s syndrome (trisomy of chromosome 21)
followed by the linking of some cases of familial AD to chro-
mosome 21 (Goate et al., 1989; St George-Hyslop et al., 1990),
that lead to the identification of the first mutations in the APP
gene (Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell
et al., 1991) (Figure 1). Since then, more than 20 pathogenic
mutations have been identified, they however account for only
a minority of familial AD cases. Most mutations are in the
presenilin 1 (PSEN1) and PSEN2 genes, and until today, over
130 mutations have been identified (http://www.molgen.ua.ac.
be/admutations/). The familial cases altogether account for less
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FIGURE 1 | Timeline of the landmark discovery of Alzheimer plaques
and tangles made by Alois Alzheimer in 1906, followed by the
identification of Aβ and tau as principal plaque and tangle components,
respectively, over 70 years later. Another decade later, the first pathogenic
mutations were identified in the APP and PSEN genes in Alzheimer’s disease
(AD) (1989), and nine years later in the MAPT gene in a subset of cases
with frontotemporal dementia (FTD) (1998). APP encodes the amyloid
precursor protein from which Aβ is derived by proteolytic cleavage, and PSEN
encodes presenilin, one of four component of the secretase complex that
generates Aβ. Tau is a microtubule-associated protein encoded by the
MAPT gene. The microscope used by Alzheimer is shown as well as
representative images of plaques and tangles. None of the
currently available drugs prevent or delay the neuronal degeneration that
characterises AD and FTD as they do not target the underlying biology.
Functional genomics approaches in experimental cellular and animal systems
are expected not only to contribute to a better understanding of how Aβ and
tau cause neuronal demise, but also to assist in developing more effective
therapies.
than 1%. Of the many susceptibility or risk genes identified in
AD, apolipoprotein E (ApoE) is the most important one (Kim
et al., 2009). The human ApoE gene contains several single-
nucleotide polymorphisms (SNPs) that are distributed across
the gene (Nickerson et al., 2000). The most common three
SNPs lead to changes in the coding sequence and result in the
three common isoforms of apoE: apoE2 (Cys112/Cys158), apoE3
(Cys112/Arg158), and apoE4 (Arg112/Arg158). Although they
differ by only one or two amino acids at residue 112 or 158,
these differences alter the apoE structure and function profoundly
(Mahley et al., 2006). The increased risk for AD is 2- to 3-fold in
people with one ApoE4 allele, and about 12-fold in individuals
with two ApoE4 alleles (Roses, 1996). In fact, as 64% of sporadic
AD cases are ApoE4 carriers, this allele comprises a major risk
factor in AD.
As for Aβ, it took several years until it was recognized that the
filaments that make up the neurofibrillary tangles are composed
of hyperphosphorylated forms of the protein tau (Brion et al.,
1985; Delacourte and Defossez, 1986; Grundke-Iqbal et al., 1986;
Ihara et al., 1986; Kosik et al., 1986; Goedert et al., 1988; Wischik
et al., 1988) (Figure 1). This protein exists in the murine brain
as three major splicing isoforms that all have four microtubule-
binding repeats (4R) in common and contain either no, one or
two amino-terminal inserts, termed E1 and E2 (creating the iso-
forms 0N/4R, 1N/4R, and 2N/4R), whereas, in humans, there is,
in addition, a set of three 3R isoforms, resulting in a total of six
major isoforms (Gotz et al., 2010). Tau is enriched in neurons,
but it is also expressed in other cell-types such as oligodendrocytes
where it is required for the outgrowth of cellular processes and the
kinase Fyn-dependent myelination of neurons (Klein et al., 2002).
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In the course of neuronal maturation, tau segregates into the
axon, and the family member MAP2 into the dendrites (Matus,
1990).
Tau belongs to the family of microtubule-associated proteins
(MAPs) (Dehmelt and Halpain, 2005), with different models
being put forward to explain how it might bind to microtubules
(Al-Bassam et al., 2002; Magnani et al., 2007). Although tau is
widely considered as an axonal protein, it has been suggested
that a physiological role must exist for tau outside the axonal
compartment (Loomis et al., 1990). The view is slowly emerg-
ing that tau is in fact an important scaffolding protein with a
range of functions in the physiological context (Bi et al., 2011;
Ittner and Gotz, 2011; Gotz et al., 2012). For example, we showed
that under normal conditions tau is found albeit at low lev-
els in dendrites (Ittner et al., 2010). We further found that tau
targets the kinase Fyn to the dendritic compartment, with this
kinase phosphorylating the NMDA receptor and thereby medi-
ating its interaction with the post-synaptic density protein 95
(PSD-95) (Ittner and Gotz, 2011). Tau has also been detected
on ribosomes of both neuronal and glial cells (Papasozomenos
and Su, 1991). We found further that tau affects mitochondrial
functions mainly via complex I of the respiratory chain (David
et al., 2006; Eckert et al., 2008; Rhein et al., 2009; Eckert et al.,
2010). After tau was first identified in 1975 (Weingarten et al.,
1975), tau research mainly investigated physiological functions.
However, the focus shifted radically when tau was identified as
the filamentous core of the neurofibrillary tangles. Insoluble tau
aggregates are present inmany diseases other thanAD, collectively
termed tauopathies, where they occur in the absence of overt Aβ
deposition (Gotz and Ittner, 2008). Tau has an unusually high
content of 84 putative phosphorylation sites, and under patho-
logical conditions, the protein becomes “hyperphosphorylated”,
i.e., some sites become phosphorylated to a higher degree in the
diseased than in the healthy brain; others are de novo phospho-
rylated (Chen et al., 2004a). These phosphorylation events are
required for tau to detach from the microtubules, tau is relocal-
ized from the axon to the somatodendritic compartment, and
as soluble tau levels increase, it interacts with cellular proteins
and prevents them from executing their normal functions (Ittner
et al., 2009; Stoothoff et al., 2009; Ittner et al., 2010). While
in AD, no mutations have been identified in the MAPT gene
encoding tau, until today, over 40 intronic and exonic muta-
tions have been identified in FTD with Parkinsonism linked to
chromosome 17 (FTDP-17), a form of FTLD-Tau (Hutton et al.,
1998; Poorkaj et al., 1998; Spillantini et al., 1998) (Figure 1).
This established that dysfunction of tau by itself can cause neu-
rodegeneration and lead to dementia. A second major subset
of FTLD is characterized by lesions that are tau-negative and
ubiquitin-positive. In this subset, the transcription and splicing
factor TDP-43 (TAR DNA-binding protein 43) was identified
as the aggregating protein and hence, this form of disease was
termed FTLD-TDP (Neumann et al., 2006). Similar to tau, TDP-
43 in the aggregates is hyperphosphorylated and fragmented, a
process believed to be linked to toxicity (Neumann et al., 2006;
Zhang et al., 2007; Dormann et al., 2009; Igaz et al., 2009). Finally,
in a third subset of FTLD, FTLD-FUS, a second nuclear pro-
tein, FUS (Fused-in-Sarcoma), was identified as the aggregating
protein (Urwin et al., 2010). While both proteins form aggregates
also in subsets of amyotrophic lateral sclerosis (ALS), the mecha-
nisms causing disease are believed to differ (Dormann and Haass,
2011). Interestingly, while in FTLD-tau tau is relocalized from the
axon to the somatodendritic domain, in FTLD-TDP and -FUS,
there is a nucleo-cytoplasmic relocalization of TDP-43 and FUS,
respectively. What causes these proteins to form aggregates in the
first place is not understood nor why, e.g., in one disease it is
FUS that is aggregating while in another disease the aggregating
protein is tau.
Of the many post-translational modifications tau undergoes,
phosphorylation seems to be the most important one, pointing
at the deregulation of kinases and phosphatases as being crucial
in the pathogenesis of AD (Chen et al., 2004a). Tau not only
contains an unusually high content of putative phosphorylation
sites (45 serines, 35 threonines and 4 tyrosines for the longest 441
amino acid human tau isoform, htau40)—it is also highly phos-
phorylated under physiological conditions, having on average 2–3
moles of phosphate per mole of tau, while under pathological
conditions this ratio is increased to 7–8moles (Kopke et al., 1993).
This pathological change has been termed “hyperphosphoryla-
tion” (Pettegrew et al., 1987): some sites are phosphorylated to
a higher degree in the diseased compared with the healthy brain,
while others are de novo phosphorylated. Hyperphosphorylation
is critical for tau to detach from microtubules and believed to be
a prerequisite for aggregation (Avila, 2006). Potential therapeu-
tic strategies are directed at a wide variety of kinases, including
glycogen synthase kinase 3β (GSK3β), cyclin-dependent kinase
5 (Cdk5), JNK, and microtubule-associated regulatory kinase
(MARK) (Dolan and Johnson, 2010). Kinase activities are antag-
onized by phosphatases and for tau they include protein phos-
phatase 2A (PP2A) and protein phosphatase 2B (PP2B) that is
also known as calcineurin (Kins et al., 2003). PP2A binds to
tau directly, and this binding is mediated by tau’s microtubule-
binding domain (Sontag et al., 1996; Xu et al., 2008). Below we
will discuss studies addressing the complex role of these enzymes
in AD and how they interact.
GENETIC AND BIOCHEMICAL DISCOVERIES PAVE THE
WAY FOR ANIMAL MODEL DEVELOPMENT
While significant insight into disease mechanisms has been
obtained in invertebrate species such as the roundworm C. ele-
gans or the fruitfly D. melanogaster, the mouse has been and
still is the major species used in AD and FTLD research (Gotz
and Gotz, 2009). With the identification of the first pathogenic
mutations in the APP gene in familial cases of AD, a plethora of
APP mutant mouse strains has been generated, with prominent
examples being strains such as PDAPP, J20, APP23, or Tg2576,
all of which are characterized by a robust Aβ plaque pathology
(Games et al., 1995; Hsiao et al., 1996; Sturchler-Pierrat et al.,
1997; Mucke et al., 2000). Representative models with neurofib-
rillary tangle formation include strains such as the JNPL3 or
our pR5 mice, both of which express P301L mutant tau that
is found in familial cases of FTDP-17 (Lewis et al., 2000; Gotz
et al., 2001a). In the mouse models, Aβ in the plaques is fibrillar,
as is tau in the tangles; and in both instances, the histopathol-
ogy is associated with behavioral impairment (Gotz and Ittner,
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2008). In plaque-forming APP23 mice, the age-dependent cogni-
tive decline has been found to precede amyloid deposition (Van
Dam et al., 2003). In tangle-forming pR5 mice, owing to a pro-
nounced pathology in the amygdala and hippocampus (Deters
et al., 2008), the behavioral impairment was found to correlate
with tau aggregation rather than tangle formation which occurred
only in a relatively small subset of neurons (Pennanen et al., 2004,
2006).
There is a crosstalk between glucose metabolism (that is
deregulated in another epidemic, diabetes mellitus) and the AD
pathology as illustrated in mice: when APP23 mice were crossed
with diabetic ob/ob mice to establish double-mutant mice, the
onset of diabetes was found to exacerbate the cognitive dysfunc-
tion already at 8 weeks of age and without an increase in brain
amyloid-beta burden (Takeda et al., 2010). In pR5 mice, in com-
parison, inducing diabetes by injecting streptozotocin increased
tau’s hyperphosphorylation and insolubility, and accelerated tan-
gle formation arguing that diabetes can accelerate the onset and
increase severity of disease in individuals with a predisposition to
developing tau pathology (Ke et al., 2009).
While the pR5 mice display memory impairment as a major
clinical feature of AD, another feature, Parkinsonism, that char-
acterizes a significant subset of FTLD cases, has been modeled
in K369I mutant tau transgenic K3 mice. We established this
strain based on the identification of the K369I mutation of tau
in a single patient with PiD (Neumann et al., 2001), and repro-
duced the distinct characteristics of Pick’s pathology in mice
(Ittner et al., 2008). Memory functions were impaired as shown
in the novel object recognition test. Owing to a unique expres-
sion pattern of the transgene that extends to the substantia nigra,
the K3 mice also model early-onset Parkinsonism, i.e., resting
tremor, bradykinesia, postural instability, and gait anomalies.
They show an increased cataleptic response to haloperidol and
an early, but not late response to L-Dopa, indicating that the
dopaminergic system is impaired.We found a selectively impaired
axonal transport of distinct cargos including mitochondria and
TH (tyrosine hydroxylase)-containing vesicles. At the molecular
level, this is caused by trapping of the adapter protein Jip1, a
component of the kinesin motor machinery, by elevated levels of
phosphorylated tau, preventing Jip1 from executing its physio-
logical function in the axon (Ittner et al., 2008). A pathological
interaction between tau and JIP1 was further revealed in AD and
not, control brain, highlighting the validity of transgenic animal
models in dissecting pathomechanisms in AD (Ittner et al., 2009).
We have been using the K3 mice for an ENU mutagenesis screen
as outlined below.
Several aspects of the human AD and FTLD pathology have
been successfully modeled in the nematode C. elegans (Morcos
and Hutter, 2009). This roundworm has a number of features
that make it a powerful research tool, complementing, but not
replacing the mouse as a model organism: (1) it is easy to cul-
ture as it feeds of bacteria grown on agar plates; (2) it reproduces
and develops rapidly: within 3 days it develops from an egg
to an adult worm, with about 300 progenies originating from
one self-fertilized hermaphrodite; (3) its small size allows assays
in microtitre format, studying hundreds of animals in a sin-
gle well; (4) the worm is transparent, which is ideal for the
use of fluorescent markers in vivo; (5) although it is a com-
plex multicellular animal, an adult hermaphrodite has only 959
somatic cells that form all the organs, including 302 neurons
that form the nervous system; (6) it has a short live span of 2–3
weeks, allowing aging studies within a reasonable time frame;
and (7) genetic modifications, such as transgenic expression or
RNAi-mediated gene knockdown are relatively easy compared to
other in vivo systems. Furthermore, most human disease genes
and pathways are present in C. elegans (Kaletta and Hengartner,
2006). This includes the APP homologue APL-1, a mutation of
which results in early larval lethality (Hornsten et al., 2007),
which can be rescued by a carboxy-terminal truncation suggest-
ing that the extracellular region of the protein is essential for
viability (Wiese et al., 2010). These similarities prompted inves-
tigators to structurally characterize the E2 domain of APL-1 and
draw conclusions for the still elusive physiological function of its
mammalian homolog APP in binding to the heparan sulfate pro-
teoglycans and hence, adhesion (Hoopes et al., 2010). C. elegans
has two presenilin homologs, SEL-12 and HOP-1 (Levitan and
Greenwald, 1995; Li and Greenwald, 1997), and a single MAP
called ptl-1 (protein with tau-like repeats) that is the homolog
of both tau and MAP2 (Goedert et al., 1996; McDermott et al.,
1996).
C. elegans has been successfully used as a model organism
to study pathomechanisms in AD and FTLD. Expression of
human tau carrying FTLD mutations, but not wild-type tau,
results in neurodegeneration with an accumulation of hyperphos-
phorylated tau and associated uncoordinated locomotion (Unc)
(Kraemer et al., 2003; Miyasaka et al., 2005; Brandt et al., 2009).
C. elegans is not capable of producing endogenous Aβ. When the
first published transgenic model targeted Aβ to the body wall of
muscle cells, this caused progressive paralysis (Link, 1995). Aβ
deposition in another model was associated with oxidative stress
(Drake et al., 2003). A further aspect linked to oxidative stress that
is evident from studies in C. elegans is the similarity between dia-
betes mellitus and AD, in particular with regards to the formation
of advanced glycation end products (Morcos and Hutter, 2009).
Taking epidemiological studies a step further that had suggested
that caffeine consumption may reduce the AD risk, it was found
by screening in worms that it is not caffeine that is protective but
rather the activation of the highly conserved skn-1/Nrf2 detoxifi-
cation pathway (Dostal et al., 2010). An interesting recent study
looked at the role of protein homeostasis in longevity (Alavez
et al., 2011). C. elegans is a preferred system to study ageing and
genetic determinants in longevity which again informs on suscep-
tibility to neurodegeneration (Freude et al., 2009; Reis-Rodrigues
et al., 2012). It was found that small molecules such as thioflavin
T (ThT), a dye traditionally used in histopathology to stain amy-
loid in tissues, not only slowed protein aggregation in vitro and in
cell culture, but also profoundly extended the lifespan and slowed
ageing in C. elegans via regulators of protein homeostasis (Alavez
et al., 2011). Together this demonstrates the potential ofC. elegans
as a model organism in AD and FTLD research.
The findings obtained in the worm are complemented by stud-
ies in Drosophila, a powerful system to screen for modifiers that
either enhance or suppress an AD-associated pathology (Shulman
and Feany, 2003; van de Hoef et al., 2009). Drosophila has been
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instrumental in determining the role of phosphorylation in tau
aggregation (Steinhilb et al., 2007) and in providing direct evi-
dence for DNA damage and checkpoint activation in tauopathies
(Khurana et al., 2012). Interestingly, the pathological changes in
the mouse are mirrored by those found in the experimentally
more accessible worm. Together this raises the possibility of a
generally protective function for the DNA damage checkpoint in
diseases of aging.
THE ADVENT OF FUNCTIONAL GENOMICS—SUPPORT
FOR PREVAILING HYPOTHESES AND IDENTIFICATION
OF NEW TARGETS
With the advent of multiplex techniques in functional genomics,
both transcriptomic and proteomic approaches have been
increasingly applied in the field (Hoerndli et al., 2005; David
et al., 2005a). As the currently prescribed drugs are symptomatic
(Figure 1) and altogether over two dozen clinical trials have failed,
one of the hopes is that the screening efforts will not only con-
tribute to a basic pathogenic understanding but may also help in
identifying new drug targets, thereby complementing the newer
treatment strategies that aim to reduce the levels of either Aβ
or hyperphosphorylated tau (Ballard et al., 2011). Functional
genomics approaches have been particularly helpful in deter-
mining the downstream toxic consequences of increased Aβ and
tau levels and target these for therapeutic intervention. Not sur-
prisingly, category analysis identified some usual suspects and
pathways, however, as we will outline, they also identified novel
potential drug targets. One of the major challenges resides in
determining what the relative contribution is of the different
molecules and mechanisms, as some of the deregulated genes and
proteins have roles in general mechanisms such as axonal trans-
port, the MAPK signaling pathway, mitochondrial function, cell
cycle regulation, and so forth (Gotz and Gotz, 2009). Only slowly
it is becoming clear what the relative role is of Aβ and tau in caus-
ing neuronal toxicity in the first place, and therefore it will take a
while until the role of their down-streammediators will be unam-
biguously determined (Gotz et al., 2008). Obviously, with therapy
in mind, one might also regulate Aβ and tau directly, either at
the transcriptional, translational or post-translational level. Here,
miRNAs are newly emerging therapeutic tools (Zovoilis et al.,
2011).
In AD not all brain areas are affected equally by degeneration.
In fact, the progression of lesions such as of the neurofibrillary
tangles has led to the definition of the so-called Braak stages, as
tangle formation is initiated in the entorhinal cortex and spreads
from there in a stereotypic fashion to the hippocampus and even-
tually to anatomically linked higher cortical brain regions (Braak
and Braak, 1991). This has led to coining of the term “selec-
tive vulnerability” raising the possibility that because of a specific
genetic “make-up” some brain areas are more prone to degen-
eration while others are relatively resistant (Gotz et al., 2009).
By assessing the brain of experimental species such as mice,
an essential question therefore is to which extent there is brain
region-specific gene expression in the first place. When the hip-
pocampal subregions CA1, CA3, and DG of wild-type mice were
analysed by gene arrays and qRT-PCR, the maximal difference
observed for any gene was 7.6-fold and none of the genes seemed
to be transcribed exclusively in any of these subregions (Zhao
et al., 2001). In a related study using gene arrays and Northern
blotting of cortex, cerebellum and midbrain, less than 1% of
the genes showed a clear enrichment and for the cerebellum, for
example, only 14 genes showed a restriction or high expression,
while 14 other genes were completely absent (Sandberg et al.,
2000). Interestingly, different from the cerebellum, the structures
of the medial temporal lobe (i.e., hippocampus, amygdala and
entorhinal cortex) showed very similar expression profiles and
only eight genes were unique to one of the three regions. This
would suggest that forebrain structures, despite some functional
differences, are highly similar at the molecular level (Sandberg
et al., 2000). It has to be kept in mind that with the more sensitive
methods that are available today (such as high density arrays and
in particular RNA sequencing) these numbers may change drasti-
cally (Ramskold et al., 2012). In two complementary studies, the
amygdala has been shown to be a hotspot for Aβ-mediated tau
tangle formation in mice suggesting a role for differential gene
expression in vulnerability to Aβ (Lewis et al., 2001; Gotz et al.,
2001b). Furthermore, the behavioral impairment was correlated
with the presence of tau aggregates in distinct subnuclei of the
amygdala (Pennanen et al., 2004). In support, a microarray anal-
ysis found that although in wild-type mice on average only 0.3%
of the 34,000 genes interrogated were highly enriched in each of
the five regions analysed (that included the amygdala), in situ
hybridization performed on a subset of the amygdala-enriched
genes mostly confirmed the overall region-specificity predicted
by the microarray data, revealing boundaries of expression within
the amygdala that corresponded to cytoarchitectonically defined
subnuclei (Zirlinger et al., 2001). In AD, however, selective vul-
nerability in AD may be of a multigenic nature. Nonetheless,
distinct genes with protective function may have the potential
of being exploited for therapeutic intervention (Greeve et al.,
2000).
Several hypotheses have been put forward to explain neu-
rodegeneration in AD. While the amyloid cascade hypothesis has
had a major impact in the field [by placing Aβ in a pathocas-
cade upstream of tau (Hardy, 2006)], work from several groups
revealed an essential role for tau in mediating Aβ toxicity (Ittner
et al., 2010; Rapoport et al., 2002; Roberson et al., 2007). More
specifically, removing tau from the dendritic compartment res-
cued Aβ plaque-forming mice from increased lethality, impaired
memory functions and increased susceptibility to excitotoxic
seizures (Roberson et al., 2007; Ittner et al., 2010; Ittner and
Gotz, 2011). Excitotoxicity has been implicated in AD, leading
to excessive nitric oxide (NO) levels, which causes down-stream
protein misfolding and aggregation, as well as oxidation damage
of mitochondria. Support for the oxidation damage hypothesis
that overlaps with the impaired axonal transport hypothesis is
provided by functional genomics approaches in both cellular and
animal models.
Not surprisingly, oxidative stress and mitochondria are gain-
ing increasing attention in diseases affecting the nervous system
(Marazziti et al., 2012). Mitochondria are dynamic organelles
that move from the cell body to regions of the cell to deliver
ATP and other metabolites where they are most required, and
then return. This is seen most strikingly in highly elongated cells
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such as neurons: mitochondria are enriched at presynaptic ter-
minals at the ends of axons and at post-synaptic terminals at
the ends of dendrites, where the bioenergetic demand is particu-
larly high (Schon and Przedborski, 2011). A recent study provides
transcriptomic and proteomic evidence that the neuronal nuclear
genes influencingmitochondrial energy metabolism are underex-
pressed in AD, particularly in brain regions like the posterior cin-
gulate cortex, which are found to be preferentially affected in PET
studies of AD patients and cognitively normal persons at genetic
risk for this disorder (Liang et al., 2008). A MALDI TOF/TOF
mass-spectrometric analysis of P301L tau transgenic pR5 mice
revealed a deregulation of mainly metabolic-related proteins
including mitochondrial respiratory chain complex components
(including the complex V component ATP synthase D chain),
antioxidant enzymes and synaptic proteins (David et al., 2005b).
Deregulated kinases were not observed possibly reflecting gen-
erally low protein levels of these enzymes. However, indirect
changes were found such as decreases of GRB2, an adapter
protein involved in the activation of the mitogen-activated pro-
tein kinase signaling pathway. A subsequent functional analysis
demonstrated a mitochondrial dysfunction in pR5 mice together
with reduced NADH-ubiquinone oxidoreductase activity and,
with age, impaired mitochondrial respiration and ATP synthe-
sis. Mitochondrial dysfunction was associated with higher levels
of reactive oxygen species in aged transgenic mice and an up-
regulation of antioxidant enzymes. When complex V levels were
analyzed in human FTDP-17 patient brains carrying the P301L
tau mutation a significant decrease was found in all P301L brain
samples compared to controls underscoring the validity of the
proteomics findings for the human disease. Importantly, pR5
mitochondria displayed an increased vulnerability towards Aβ,
suggesting a synergistic action of tau and Aβ pathology on the
mitochondria (David et al., 2005b). A serial analysis of gene
expression (SAGE) of the same mouse strain looking specifically
at the amygdala also revealed deregulated mitochondrial genes
(Ke et al., 2012). Furthermore, the β catalytic subunit of protein
phosphatase 3 (encoded by Ppp3cb) was 2-fold down-regulated in
the pR5 mice, while CDC-like kinase 1 was more than 4-fold up-
regulated (Ke et al., 2012). When vesicular fractions were isolated
from Aβ plaque-forming Tg2576 mice, and proteins separated
by 2-D DIGE and identified by mass spectrometry followed by
a functional validation, this identified numerous changes in the
protein subunit composition of the respiratory chain complexes
I and III, impaired state 3 respiration and uncoupled respiration
(Gillardon et al., 2007), similar to what has been found in P301L
tau transgenic pR5 mice (David et al., 2005b) and Aβ plaque-
forming Thy-1.APP transgenic mouse strain (Hauptmann et al.,
2008). As this impairment occurred before NFT formation and
Aβ plaque deposition it suggests that mitochondria are early tar-
gets of Aβ and tau aggregates (Eckert et al., 2011). To address
the cross-talk of Aβ and tau on mitochondrial functions, pR5
mice were bred with Aβ plaque-forming APPswPS2N141I double-
transgenic APP152 mice to generate triple transgenic (tripleAD)
mice that combine both pathologies in one model (Grueninger
et al., 2010). Quantitative mass-tag labeling (iTRAQ) followed
by mass spectrometry revealed a massive deregulation of 24
proteins of which one third were mitochondrial proteins mainly
related to complexes I and IV of the oxidative phosphorylation
system (OXPHOS). Notably, deregulation of complex I was tau-
dependent, while deregulation of complex IV was Aβ-dependent,
both at the protein and activity levels (Rhein et al., 2009). In
addition, synergistic effects of Aβ and tau were evident in the
tripleAD mice establishing a molecular link between Aβ and tau
protein in AD pathology in vivo (Rhein et al., 2009). In the
mice, phosphorylation of tau at the epitope Ser422 was enhanced
(Grueninger et al., 2010) and incidentally, this is an epitope that
has been tightly linked to tau tangle formation (Gotz et al.,
2001b; Ferrari et al., 2003). To determine the kinase responsi-
ble for Ser422 phosphorylation of tau, screening of a library of
65,000 kinase inhibitors was combined with in vitro inhibitor
target profiling of the screening hits using the Ambit kinase
platform: this identified the kinase MKK4 (Grueninger et al.,
2011). MKK4 is a regulatory kinase and very probably con-
trols Ser422 phosphorylation of tau via activation of one of its
immediate downstream target kinases (Grueninger et al., 2011).
To date only two kinases have been described as MKK4 sub-
strates, namely P38 and JNK, and both these kinase families are
known to phosphorylate tau at Ser422 in vitro (Goedert et al.,
1997).
Oxidation damage, inflammation and stress response are
tightly linked. When the CA1 region from AD cases was com-
pared to control subjects, an Affymetrix analysis mainly revealed
an up-regulation of oxidative stress-related, apoptosis-related
and pro-inflammatory signaling genes (Colangelo et al., 2002);
a comparative analysis of three APP mouse models by gene
arrays identified mainly deregulated genes with roles in the
immune response, carbohydrate metabolism, and proteolysis;
while in P301L tau transgenic JNPL3 mice, inflammation medi-
ators and apoptosis inhibitors were found to be down-regulated
(Ho et al., 2001). In the P301L tau transgenic pR5 mice, glyox-
alase I was the only up-regulated gene when a stringent analysis
was applied (Chen et al., 2004b). This enzyme plays a crit-
ical role in the detoxification of dicarbonyl compounds and
thereby reduces the formation of advanced glycation end prod-
ucts. Levels of both glyoxalase I mRNA and protein were signif-
icantly elevated in pR5 brains (Chen et al., 2004b). Co-staining
with a phospho-tau antibody suggested glyoxalase I upregula-
tion as an early defense mechanism to combat elevated levels
of aggregated tau. When different annotation databases were
used to compare these transcriptomic data with the SAGE anal-
ysis of RNA extracted from pooled amygdalae of P301L tau
transgenic pR5 mice (Ke et al., 2012) it was found by using
GenMAPP pathways as annotation database, that the two datasets
shared deregulated genes involved in inflammation and protea-
some degradation (Hoerndli et al., 2004). To understand which
processes are disrupted by Aß42 in the presence of tau aggre-
gates, comparative proteomics was also applied to Aß42-treated
P301L tau expressing neuroblastoma cells and the amygdala
of P301L tau transgenic pR5 mice stereotaxically injected with
Aß42: A significant fraction of proteins altered in both systems
belonged to the same functional categories, i.e., proteins involved
in the stress-response associated with protein folding (David
et al., 2006). Among the deregulated proteins was VCP (valosin
containing protein), an essential component of the ER-associated
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degradation (ERAD) process. Down-regulated were also mem-
bers of the peroxiredoxin family. For comparison, over-expression
of Aβ and amyloid binding alcohol dehydrogenase (ABAD), an
intracellular binding site for Aβ, in transgenic mice identified
deregulated peroxiredoxin 2 levels a protein subsequently shown
to be increased in the AD brain. The authors argued that the
expression level of peroxiredoxin 2 is an indicator for the inter-
action of ABAD and Aβ as its expression levels return to normal
when this interaction is perturbed, suggesting Aβ-ABAD inter-
action as a suitable drug target (Yao et al., 2007). More specif-
ically, the ABAD inhibitor AG18051 has been found to protect
SH-SY5Y neuroblastoma cells from Aβ42 toxicity (Lim et al.,
2011).
Given the critical role of mitochondria in maintaining cell via-
bility, it stands to reason that defects in mitochondrial trafficking
could underlie neurodegenerative processes; however direct evi-
dence that mitochondrial trafficking is altered in patients with
neurodegenerative disease is actually quite limited (Schon and
Przedborski, 2011). In animal models however, defects in trans-
port have been functionally addressed and there is increasing
evidence also from functional genomics studies that hint at axonal
transport and mitochondrial dysfunction as central pathome-
chanisms. In a microarray analysis of tangle-bearing neurons
several classes of mRNAs known to encode proteins implicated
in AD neuropathology were deregulated, including cytoskele-
tal and synaptic proteins, as well as glutamate and dopamine
receptors (Ginsberg et al., 2000). A few studies focused on early
changes associated with mild cognitive impairment (MCI). In
one microarray analysis of a small brain sample size, in the
superior temporal gyrus down-regulation was found for genes
encoding synaptic vesicle proteins such as synapsin IIa, and
genes involved in cytoskeletal mobility (Pasinetti, 2001). A follow-
up study using proteomics confirmed many of the changes in
proteins with synaptic activities (Pasinetti and Ho, 2001). Wild-
type mice that had undergone a standard Morris water maze
paradigm were used to identify memory-related genes. Of more
than 1000 relevant genes, 140 were hippocampal memory-related
including genes encoding glutamate receptors, ion channels and
also trafficking proteins (Cavallaro et al., 2002). Interestingly,
in the adult Down syndrome brain, gene expression profiling
identified deregulated genes with roles in processes concomi-
tant with cytoskeletal regulation and vesicle trafficking categories,
and an increased immune and oxidative stress response, which
are likely linked to the development of AD pathology in indi-
viduals with Down syndrome (Lockstone et al., 2007). When a
pilot proteomic study was performed in brain samples of patients
with AD and normal control subjects to identify APP interac-
tors, 21 proteins were identified which could be grouped into
five functional classes: molecular chaperones, cytoskeletal and
structural proteins, adaptors, enzymes, and proteins involved
in trafficking. Subsequent validation was compatible with an
involvement of APP in axonal transport and vesicular traffick-
ing (Cottrell et al., 2005). We established the K369I mutant
tau transgenic K3 mice that models memory impairment and
Parkinsonism that characterize a significant subset of cases of
FTLD (Ittner et al., 2008, 2009). Moreover, the motor phenotype
was instrumental in determining tau-mediated impaired axonal
transport of distinct cargoes including tyrosine hydroxylase-
containing vesicles and mitochondria as underlying pathome-
chanism. As in the K3 mice the motor phenotype is evident
at a very early age, clasping, tremor and postural stability can
be used as an easy readout for the efficacy of any interven-
tion be it pharmacological or genetic (van Eersel et al., 2010),
or for a modifier screening using ENU mutagenesis (Liu et al.,
2011).
A rarely used method to identify differentially expressed genes
is the above-mentioned SAGE (Velculescu et al., 1995). The
beauty of this method compared to gene chip approaches lies
in the fact that it is firstly unbiased and secondly that rather
than obtaining an endlessly long list of deregulated genes one
ends up with a rather limited number. SAGE works by tran-
scribing RNA into cDNA, followed by digestion with a type IIS
restriction enzyme that yield 10–14 base-pair long sequence tags
that are annealed followed by sequencing. By sequencing 92,000
tags we identified 29 deregulated genes in the amygdala of pR5
mice compared to controls which included Sfpq that encodes a
nuclear factor implicated in the splicing and regulation of gene
expression (Ke et al., 2012). To assess the relevance for human
disease we analyzed brains from the two tauopathies, AD and
PiD, as well as control cases. Strikingly, in AD and PiD, affected
brain areas showed a virtually complete nuclear depletion of
SFPQ in both neurons and astrocytes, along with cytoplasmic
accumulation. Accordingly, neurons harboring either AD tan-
gles or Pick bodies were also depleted of SFPQ. Immunoblot
analysis of human entorhinal cortex samples revealed reduced
SFPQ levels with advanced Braak stages suggesting that the SFPQ
pathology may progress together with the tau pathology in AD.
To determine a causal role for tau, we stably expressed both
wild-type and P301L human tau in human SH-SY5Y neuro-
blastoma cells, an established cell culture model of tau pathology
(Pennanen and Gotz, 2005). The cells were differentiated by two
independent methods, mitomycin C-mediated cell cycle arrest or
neuronal differentiation with retinoic acid. Confocal microscopy
revealed that SFPQ was confined to nuclei in non-transfected
wild-type cells, whereas in wild-type and more pronounced in
P301L tau over-expressing cells, irrespective of the differentia-
tion method, it formed aggregates in the cytoplasm, suggesting
that pathogenic tau drives SFPQ pathology in post-mitotic cells
(Ke et al., 2012). These findings add SFPQ to a growing list
of transcription factors with an altered nucleo-cytoplasmic dis-
tribution under neurodegenerative conditions highlighting RNA
mismanagement as a general pathomechanism (Patel and Chu,
2011).
While a lot of efforts have concentrated on deregulated pro-
teins and protein-encoding genes, more recently significant atten-
tion has started focusing on microRNAs (miRNAs). These are
cellular gene silencing tools that add another level of com-
plexity to gene regulation. Evolutionary conserved, these 19–24
nucleotide-long non-coding RNAs negatively regulate the expres-
sion of specific mRNA targets through base pairing between their
“seed region” and sequences commonly located in the 3′ untrans-
lated region of their targets (Fabian et al., 2010; Siomi and Siomi,
2010). In the mouse brain, there are in the order of 300 miR-
NAs expressed, and each can target up to several hundred to a
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thousand transcripts (Landgraf et al., 2007). Unfortunately, how-
ever, so far only a few targets have been confirmed in vivo (Lau
and de Strooper, 2010). The recent years have nonetheless seen
an explosion in studies linkingmiRNAs to pathological processes,
and evidence is mounting that they have a role in neurodegen-
erative diseases ranging from AD (Schonrock et al., 2011) to
Parkinson’s disease (Kim et al., 2007) and ALS (Williams et al.,
2009). After discovering the first human miRNAs (Pasquinelli
et al., 2000), it took several years until the first report on dif-
ferential miRNA profiles was published for human AD tissue
(Lukiw, 2007). Since then many groups performed genome-wide
profiling highlighting specific changes in the miRNA regulatory
system in human AD brain (Hebert et al., 2008; Wang et al.,
2008; Nunez-Iglesias et al., 2010; Shioya et al., 2010). These may
either involve neuronal or glial cells or both, as both cell types are
affected in human “neurodegenerative” conditions (Kurosinski
and Gotz, 2002). Accumulating data indicate that miRNAs act
at several levels: in the case of APP, they regulate APP mRNA
levels and have a role in alternative splicing. They further reg-
ulate APP processing indirectly via the β-secretase BACE1 that
has been identified as a miRNA target, with the miRNA cluster
containing miR-29a, -29b1, and -9 playing a crucial role (Hebert
et al., 2008; Zong et al., 2011). Conversely, Aβ itself has down-
stream effects on miRNA expression: when primary hippocampal
neurons were incubated with fibrillar preparations of Aβ42, we
found that this invoked a strong and rapid change in miRNA
profiles with a substantial proportion of miRNAs being down-
regulated. miR-9 is the most abundant human brain miRNA
(Mattick andMakunin, 2005) and a recurring candidate from sev-
eral AD profiling studies. We validated this and eight additional
miRNAs (miR-181c, -148b, -30c, -20b, -361, -21, -409-3p, and
Let-7i) as being down-regulated by Aβ42 (Schonrock et al., 2010).
Interestingly, the down-regulation of miRNAs in Aβ-treated hip-
pocampal neurons was paralleled by those in the hippocampus
of Aβ-plaque forming APP23 mice at the onset of plaque for-
mation. Another study suggests a possible transient effect of
Aβ plaque pathology on miRNA (miR-106b) expression (Wang
et al., 2010), while miR-106b was also found to regulate APP
mRNA levels (Hebert et al., 2009). Integrating all miRNA data
it seems that the miRNA network in AD is tightly regulated
by feedback loops (Schonrock et al., 2011). An ultimate chal-
lenge will be an integrated view of APP/Aβ regulation that takes
into account the role of miRNAs, mRNA transcription, transla-
tion, post-translational modifications, subcellular compartmen-
talization, brain regional differences, and changes over time,
both under physiological and pathological conditions. This will
determine whether miRNAs are merely fine-tuning instruments
as far as the major players in AD are concerned or whether
they indeed play a critical role in pathogenesis and disease
progression.
OUTLOOK—WHERE IS THE FIELD HEADING ANDWILL
FUNCTIONAL GENOMICS CONTRIBUTE TO FINDING
A CURE?
What does the future hold in store? As post-translational modi-
fications are crucial for the brain’s functioning (and in line with
“kinases” being a focus of this special “Frontiers” issue) it will be
important to move from the general proteome to the phospho-
proteome, glyco-proteome and so forth as these modifications
determine where the proteins are subcellularly targeted, with
which proteins they interact and what their activities are. It will
also be important (and as exemplified by transcriptomics) to be
able to work with increasingly smaller amounts of starting mate-
rial to determine how individual cells respond differentially to
toxic insults and how this leads to neurodegenerative changes in
some cells, and not the others. Although laser capturing allows
enriching cells of the same subtype one would ultimately like to
work with single cells. Another aspects not discussed here is that
the standard strategies do not discriminate between a protein that
has been synthesized quite a while ago and one that has been
synthesized as a consequence of a recent toxic insult. Here, novel
methods of click chemistry that allow to identify de novo synthe-
sized proteins using non-canonical amino acids will be helpful
(Dieterich et al., 2006, 2010).
Recent advances in sequencing technologies and assembly
algorithms have facilitated the reconstruction of the entire tran-
scriptome by deep RNA sequencing, and with costs going down,
these methods will certainly be more widely applied but they
will also heavily depend on bioinformatics (Martin and Wang,
2011). Neither proteins nor RNAs act in isolation and there-
fore major efforts will go in determining the cellular interactome
under normal and specific neurodegenerative conditions, includ-
ing the role of miRNAs and the interaction between RNAs in
general as well as proteins (Konig et al., 2011). A major chal-
lenge will be in integrating the proteomics and transcriptomics
findings obtained in various cellular and animal systems as well
as the human brain. It is remarkable however that despite differ-
ences in species and significant postmortem delays in humans,
one finds a remarkable overlap of deregulated genes and proteins
when comparing datasets obtained in human AD brains with
those of brains of AD mouse models. This is comforting, as it
would indicate that the functional genomics approaches in the
more accessible experimental cellular and animal systems gener-
ate data that are meaningful for the human condition. It is also
remarkable to find that functional genomics confirms the known
suspects, both at the level of the specific gene or protein, and at
the level of the deregulated category or signaling pathway. On
top of that however, functional genomics has been instrumen-
tal in identifying new players, genes and proteins that mediate or
ameliorate neurotoxicity and of miRNAs as fine-regulating tools
of gene transcription. Besides from understanding pathogenic
mechanisms, functional genomics has its merits furthermore in
identifying biomarkers that can be employed as diagnostic tools
for neurodegenerative disorders such as AD. Together, functional
genomics has had a major role in the past in understanding the
toxic roles of tau and Aβ in AD and it is expected to have a more
important role as the technology becomes more widely applied.
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